Advertisement

Reactions Weekly

, Volume 1761, Issue 1, pp 227–227 | Cite as

Lenvatinib/sorafenib

Various toxicities: 4 case reports
Case report

Reference

  1. Jerkovich F, et al. The experience of an Endocrinology Division on the use of tyrosine multikinase inhibitor therapy in patients with radioiodine-resistant differentiated thyroid cancer. Endocrine 64: 632-638, No. 3, 15 Jun 2019. Available from: URL: http://doi.org/10.1007/s12020-019-01883-3 - Argentina

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations